Published online before print December 4, 2003, doi: 10.1161/01.ATV.0000110445.95304.91
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Thrombosis |
Platelets of Female Mice Are Intrinsically More Sensitive to Agonists Than Are Platelets of Males
From Medicine/Thrombosis Research, Baylor College of Medicine, Houston, TX.
Correspondence to Dr Paul F. Bray, Thrombosis Research Section, Baylor College of Medicine, One Baylor Plaza, BCM 286, N1319, Houston, TX 77030. E-mail pbray{at}bcm.tmc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— It has been reported that women fare worse after ischemic coronary events, but the mechanisms remain unclear. Because platelets play a central role in the formation of occlusive thrombi at sites of ruptured atherosclerotic plaques, we studied male/female paired mouse littermates for sex differences in platelet function.
Methods and Results— We compared platelet reactivity in male/female mouse littermates by monitoring agonist-induced fibrinogen (FGN) binding and platelet aggregation. Compared with the platelets from males, platelets from females bound more FGN in response to low concentrations of thrombin and collagen-related peptide. Female platelets also demonstrated greater aggregation in response to adenosine diphosphate and collagen-related peptide. Platelet protein tyrosine phosphorylation on activation also showed small differences between sexes. These differences are independent of platelet size and surface expression of 
IIbß3 and GPIb-IX-V, and they were not blocked by apyrase or aspirin. The sex differences we observed were intrinsic to platelets, because they were observed in washed platelets, but not when platelets were in plasma.
Conclusions— The platelets of female mice were more reactive than those of males in a manner independent of COX-1 and secreted ADP.
Key Words: platelet • thrombin • collagen-related peptide
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Coronary heart disease is the most common cause of morbidity and mortality among American women. Although symptomatic coronary artery disease develops in women
5 to 10 years later than in men,1 the prognosis is worse for women after myocardial infarction,2 coronary revascularization,3 or thrombolytic therapy.4 A number of social, anatomic, and physiological mechanisms have been postulated to explain this gender difference,5 but the mechanisms responsible remain largely unknown. Platelets play a central role in the formation of occlusive thrombi in atherosclerotic coronary arteries,6 and gender differences in platelet reactivity have been reported in a small number of studies. Female platelets have been shown to be hyperreactive compared with male platelets in some studies,7,8 but not in others9,10 However, these studies have been rather small, and none considered confounding variables that affect platelet function (eg, cigarette use, plasma factors, and so forth). Animal models of coronary heart disease are now commonplace, and some have addressed possible sex differences in thrombus formation. Intravenous injection of arachidonic acid or the stable thromboxane A2 analog U46619 have shown a greater mortality rate in male compared with female rats, mice, and rabbits.11–13 These in vivo systems are difficult to interpret mechanistically because none has addressed which tissues (platelets, endothelial cells, smooth muscle cells, etc) and systems (inflammation, coagulation, fibrinolysis, vasoconstriction) are influenced by sex. In addition, the thrombosis reported in these in vivo models occurs in the pulmonary and not coronary vasculature,14 raising concerns about their relevance to coronary heart disease. Importantly, these in vivo approaches have not specifically addressed whether platelets contribute to the sex difference in thrombosis.
Only a few studies have isolated animal platelets for in vitro assays of sex differences, and conflicting results have been obtained. Johnson et al observed greater in vitro aggregation of platelets from male than female rats.15 However, others have observed no sex difference16 or female hyperreactivity in rat platelets.17 Gender-specific differences in the porcine platelet content of vasoactive factors and in interactions with the vessel wall have consistently been observed.18,19 The only in vitro study using mouse platelets showed no sex difference to U46619, but rather a greater slope of aggregation in male platelets to high-dose adenosine diphosphate (ADP) and arachidonic acid.13 But these in vitro studies of mouse platelet function were performed in plasma, making it impossible to assess whether the sex difference is intrinsic to platelets or to plasma.
Our goal in this study was to test the hypothesis that there are sex differences intrinsic to murine platelets. Recognizing that the mouse system is not a perfect model for the human, it nevertheless offers certain advantages. There is less heterogeneity because laboratory mice are subject to fewer environmental alterations than humans, who encounter numerous variables affecting platelet function. Studying male/female paired littermates of inbred mice also minimizes genetic and environmental differences. We found that compared with those of males, platelets from female mice are hyperreactive to multiple agonists using multiple assays.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Prostaglandin E1, aspirin, and indomethacin were purchased from Sigma (St. Louis, MO). Fluorescein isothiocyanate (FITC)-conjugated antibodies (anti-mouse CD41 and CD62) were obtained from BD Pharmingen (San Diego, CA). The blocking hamster mAb 1B5 (anti-murine
IIbß3), polyclonal anti-PAR3 IgG,20 and thrombin were gifts from Dr. Barry S. Coller (The Rockefeller University, New York, NY), Dr. Shaun R. Coughlin (University of California, San Francisco) and Dr. John Fenton (New York State Department of Health, Albany), respectively. Collagen-related peptide was synthesized at Baylor College of Medicine and cross-linked with glutaraldehyde. PAR4 activation peptide (PAR4AP) AYPGKF was synthesized at Baylor College of Medicine as carboxyl-terminal amides, purified by high-pressure liquid chromatography, and characterized by mass spectroscopy. Human fibrinogen (FGN) was from Enzyme Research Laboratories (South Bend, IN). FITC-conjugated (Pierce, Rockford, IL) FGN was made as previously described.21
Animals and Platelet Preparation
All animal studies were performed in accordance with institutional guidelines. In all studies, 9 to 12-week-old C57BL/6J female mice were compared pairwise with male littermates. Blood (0.6 mL) was collected from the inferior vena cava of isoflurane-anesthetized mice into 3.8% sodium-citrate. Whole blood was diluted with an equal volume of HEPES Modified Tyrode’s buffer (TH buffer: 12 mmol/L Na bicarbonate, 138 mmol/L NaCl, 5.5 mmol/L glucose, 2.9 mmol/L KCl, 10 mmol/L HEPES, pH 7.4) containing 0.38% citrate, and centrifuged at 50 g for 10 minutes at room temperature. The platelet-rich plasma was recovered and centrifuged at 350 g for 5 minutes. The supernatant was removed and the resulting platelet pellet was rinsed with TH/0.38% citrate buffer and resuspended in TH buffer at a concentration of 2.5x108/mL.
Flow Cytometry Analysis
Platelets were defined by their forward- and side-scatter characteristics. Platelet FGN binding was performed essentially as previously described.21 Washed platelets were diluted with TD buffer (TH buffer with 0.4 mmol/L MgCl2, 0.8 mmol/L CaCl2) to 2.5x107/mL. FITC-conjugated FGN (100 µg/mL) was added to diluted platelets before activation with agonists. After fixation with 1% paraformaldehyde, samples were analyzed with a FACSort flow cytometer (Becton-Dickinson). Mean fluorescence intensities (MFI) of platelets were recorded. Baseline (10 MFI) and non-specific binding (10 MFI and very close to baseline) were defined as binding obtained with no agonist and with agonist in the presence of 10 mmol/L EDTA, respectively. In some experiments, platelet-rich plasma was pretreated with 1 mmol/L acetylsalicylic acid (ASA) for 30 minutes at 37°C and then washed. Other inhibitors were added to platelets 2 to 3 minutes before the agonist was added. All experiments were performed in duplicate or triplicate. Results are presented either using the MFI or as a ratio of female-to-male FGN binding, as explained in Results. When MFI was used, the specific MFI (MFI sample-MFI non-specific) values were used.
Integrin IIb was quantified using washed platelets with and without activation by thrombin in the presence of FITC-conjugated anti-IIb (anti-CD41) antibody. Surface expression of PAR3 was assessed using flow cytometry as described.22 Briefly, fixed platelets were incubated with anti-PAR3 IgG (10 µg/mL) for 1 hour, washed, incubated with FITC-conjugated goat anti-rabbit IgG, and analyzed by flow cytometry. Surface expression of P-selectin (CD62) was determined using FITC-conjugated anti-CD62, and the percent positive cells was determined as described.23
Platelet Aggregation
Platelet aggregation was determined in a Bio/Data aggregometer as described.24 When aggregations were performed on washed platelets, it was necessary to add FGN, which serves as a ligand to cross-link platelets and is the most important physiological ligand mediating platelet aggregation in plasma. Human FGN is considered a useful surrogate for mouse FGN, because it demonstrates the same receptor specificity.25–28 Briefly, washed platelets were resuspended at 2.5x108/mL in TH buffer with 0.005 U/mL apyrase to prevent desensitization28–30 and allowed to rest for 1 hour. Platelet suspensions were activated by the indicated agonists in the presence of 50 µg/mL human FGN, 0.8 mmol/L calcium, and 0.4 mmol/L magnesium.25–28
Statistical Analysis
Statistical analyses were performed using StatView software (SAS Institute, Cary, NC). The collagen-related peptide-induced FGN binding, and collagen-related peptide and ADP-induced platelet aggregation data were analyzed by ANOVA for the main effect of sex. Because of the day-to-day variation in absolute MFI in the thrombin-stimulated platelet FGN binding assays, these data were nonparametric and the Wilcoxon signed rank test was used to test for differences between the groups. Results are reported as the mean±SEM; P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Sex Differences in Platelet Reactivity to Thrombin
To determine whether mice exhibit intrinsic sex differences in platelet function, washed platelets from male/female paired littermates were tested for their reactivity to thrombin. Because of the inherent day-to-day variability in many parameters of the thrombin-induced platelet FGN binding assay, the values for a particular day could be compared only with controls performed simultaneously. We designed our experiments so that paired female/male littermates were sacrificed at the same time and platelets were processed and activated side-by-side to focus on the comparison (the relative reactivity, not the absolute binding) between sexes. In this case, ratios of FGN bindings (female/male) for each thrombin concentration were obtained daily, allowing us to compare ratios obtained on different days. We found that platelets from female mice on average bound 50% more and 21% more FGN than platelets from their male littermates at 0.005 U/mL and 0.01 U/mL thrombin, respectively (Table 1, column 2). However, the difference between sexes was gradually lost with increasing concentrations of thrombin. Table 1 also shows the numbers of experiments in which female (or male) mice bound more FGN than male (or female) mice. When comparing the raw MFI FGN binding data in this manner, platelets from female mice consistently bound more FGN than platelets from male mice (P<0.0001). The sex difference in FGN binding was abolished by the
IIbß3 blocking monoclonal antibody 1B5 (Figure 1A) and by the IIbß3 antagonist eptifibatide (Integrilin) (data not shown). No sex differences were observed in either IIbß3 surface density (Figure 1B) or platelet size as measured by flow cytometric forward light scatter (96.67±1.67, n=52 females; 96.10±1.83, n=47 males).
|
|
PAR3 and PAR4 are the mouse platelet thrombin receptors.31 At low thrombin concentrations, PAR3 functions as a cofactor for the cleavage and activation of PAR4. No substantial difference in PAR3 surface expression between sexes could be detected (Figure 1C). PAR4 is the only murine PAR known to mediate transmembrane signaling in response to thrombin. Because antibodies to PAR4 were not available, we assessed PAR4 expression indirectly by measuring FGN binding in platelets activated with the PAR4 activation peptide (PAR4AP).31 We found that unlike thrombin, PAR4AP elicited no sex difference in FGN binding (Table 2).
|
Sex Difference in FGN Binding to Collagen-Related Peptide-Activated Platelets
We considered whether the sex difference in platelet responsiveness was observed with other agonists, because specificity (or no specificity) to thrombin would have important implications regarding potential mechanisms responsible for the sex difference. Cross-linked collagen-related peptide potently activates platelets through the GPVI-Fc
complex.32 Collagen-related-peptide induced greater FGN binding to female platelets than to platelets from males (Figure 2A). Thus, a second agonist produced similar findings in the same FITC-FGN binding assay.
|
Sex Difference in Platelet Aggregation
We next assessed whether a different assay would also show female platelet hyperreactivity. We observed greater ADP-induced platelet aggregation in washed platelets from the female littermates (Figure 2B). Platelets from females also demonstrated greater aggregation relative to that of males in response to collagen-related peptide in the absence of plasma (Figure 2C).
Influence of Plasma on Sex Difference in Platelet Function
Because other animal studies tested platelet aggregation only in the presence of plasma,13,15–17 we felt it important to compare platelet reactivities using washed platelets and platelets in plasma from the same mouse. Figure 2C shows the aggregation results of platelets in either buffer or plasma. The collagen-related peptide-induced aggregation showed a sex difference in the absence (P=0.03), but not the presence (P=0.86), of plasma.
Potential for Sex Differences in Platelet Signaling
Platelet activation leads to redistribution of P-selectin to the platelet plasma membrane, secretion of ADP, and generation of thromboxane A2 (the latter two feed-back to enhance platelet activation and FGN binding). When stimulated with low concentrations of thrombin, more female platelets demonstrated surface P-selectin than male platelets (data not shown). This correlated with the FGN binding data shown in Table 1. The sex difference in platelet FGN binding persisted in the presence of the ADP scavenger apyrase, although activation was suppressed in both sexes (Figure 3). In addition, the sex difference in platelet activation was not blocked by aspirin (ASA), indomethacin, or the combination of ASA and apyrase (Figure 3, indomethacin data not shown). We also examined protein tyrosine phosphorylation patterns on platelet stimulation and observed small differences between sexes in response to thrombin (Figure 4) and collagen-related peptide stimulation (data not shown), although the patterns of differentially phosphorylated proteins were not identical in response to different agonists. The differential phosphorylation between sexes was detected at earlier time points but lost with longer incubation times (not shown). We found the greatest difference between sexes was at 3 minutes of 0.005 U/mL thrombin stimulation.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mouse models have become integral reagents in the armamentarium for research on the pathophysiology of vascular diseases. Nearly 30 years have passed since the initial reports suggesting a gender difference in platelet thrombus formation,7,11,12 but this has remained a poorly studied area. Investigators have generally ignored sex as a confounding variable when analyzing their mouse models of vascular diseases. Because platelet reactivity is intimately involved in thrombus formation, inflammation, and atherosclerosis progression, it is crucial to understand the factors that affect platelet behavior. The major findings of this study were that platelets from females demonstrated greater reactivity to agonists compared with the platelets from males and that this sex effect was intrinsic to the platelets. The similarity between mouse and human with respect to this gender difference in platelet reactivity8 supports the use of mouse models of arterial thrombosis and stresses the importance of considering gender in animal and human studies of these phenotypes.
Female platelets showed a lower threshold for reactivity to thrombin than did male platelets. The relatively greater reactivity of female platelets shown as a ratio in Table 1 was not caused by a lack of reactivity of male platelets, because the latter showed an appropriate dose–response to agonists (eg, Figure 2A and B). There were no sex differences in the surface expression of platelet GPIIb and PAR3 that could account for the observed functional differences to thrombin (Figure 1B and C). In addition to the PARs, GPIb serves as a high-affinity binding site for thrombin and is involved in platelet activation.33 However, in data not shown, we observed no difference in GPIb surface expression between 11 female and 11 male C57BL/6J mice. We cannot exclude a sex difference in PAR4 levels, but this seems unlikely because the PAR4 peptide elicited no sex difference in FGN binding. Different responses to thrombin and the thrombin receptor activating peptide have been repeatedly observed in human platelets.34–36 Our study is the first to our knowledge to report that thrombin, but not the PAR4AP, displays a sex difference in mouse platelet FGN binding.
The sex difference in platelet reactivity was dose-dependant for thrombin but was present at all concentrations of ADP and collagen-related peptide tested, indicating the underlying mechanisms might be complex. Because female platelet hyperreactivity was observed with 3 different agonists, this may be a global phenomenon involving multiple molecules or a common signaling pathway shared by multiple agonists. Our FGN binding studies were performed in a very dilute platelet suspension, and low concentrations of agonists were used such that no aggregation occurred (confirmed by flow cytometry). Thus, the sex differences in platelet signaling appear to exist upstream of FGN binding to IIbß3. These sex differences in signaling were supported by the finding of differential protein tyrosine phosphorylation between sexes on platelet stimulation with thrombin and collagen-related peptide. Thromboxane A2 production appears to be non-essential for the sex difference, because the difference was not affected by ASA or indomethacin (Figure 3; data not shown). Although we observed increased expression of the granule protein P-selectin in female platelets (not shown), dense granule ADP was not required for the sex difference because the ADP scavenger apyrase did not block the sex difference. Taken together, these findings suggest that the key factors responsible for the sex difference in platelet reactivity must reside after thrombin binds to its receptor but before granule secretion.
Inconsistent results have been reported regarding sex differences in rat platelet function.15–17 These rat studies were all performed in plasma, in which males have FGN levels twice those of females.17 We are aware of only a single other in vitro study of mouse platelets, which found that male platelets had a steeper slope of aggregation to 15 µmol/L ADP than female platelets.13 Compared with our study, these investigators used a rather high dose of ADP, a different mouse strain (CD-1), slightly younger mice (50 days old), did not use paired littermates, and assessed only aggregation slope, whereas we were using sexually mature (9 to 12 weeks) C57BL/6J female/male paired wild-type littermates. Although we have not formally tested various mouse strains, our preliminary data using FVB/N mice also suggest female platelet hyperreactivity (Leng, unpublished data). Perhaps most importantly, Torres Duarte et al13 studied platelets in plasma, thereby not permitting conclusions about sex differences intrinsic to platelets. This is a crucial distinction because cross-sex transfusion studies have shown a major role for plasma in platelet accumulation in the lungs after intravenous ADP.37 Our studies have deliberately focused on platelets in isolation from plasma and other in vivo effects, and they demonstrate, for the first time to our knowledge, hyperreactivity that is intrinsic to female mouse platelets (Figure 2C). Further studies are needed to address the possibilities that plasma from male mice may favor platelet aggregation or that plasma from female mice may suppress aggregation.
Thrombosis is a multifactorial phenomenon in which multiple physiological processes (platelets, coagulation factors, endothelial cells, vasoconstriction, fibrinolysis, etc.) contribute to the final outcome. Thus, female platelet hyperreactivity may not, by itself, lead to a greater tendency toward in vivo thrombosis in females than in males. However, this could be true in some cases and it is important to understand the sex influence of each physiological component contributing to hemostasis. Although the specific mechanisms involved in greater reactivity of female platelets remain to be determined, future studies will involve examination of the potential roles of various candidate hormones (eg, estrogen, progesterone, testosterone, prolactin, and so forth) and their corresponding hormone receptors. A better understanding of the sex differences in platelet reactivity may lead to more rational preventative and therapeutic approaches to managing disorders of arterial thrombus.
|
Acknowledgments |
|---|
Acknowledgments
This study was supported in part by Baylor College of Medicine, the Fondren Foundation, NIH grant HL65967, and AHA grant 0335057N. The authors thank Junmei Chen for help with flow cytometry and K. Vinod Vijayan for helpful scientific discussions.
Received September 19, 2003; accepted November 20, 2003.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986; 111: 383–390.[CrossRef][Medline] [Order article via Infotrieve]
2. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999; 341: 217–225.
3. Loop FD, Golding LR, MacMillan JP, Cosgrove DM, Lytle BW, Sheldon WC. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol. 1983; 1: 383–390.[Abstract]
4. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA. 1996; 275: 777–782.
5. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993; 329: 247–256.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992; 326: 242–250.[Medline] [Order article via Infotrieve]
7. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975; 253: 355–357.[CrossRef][Medline] [Order article via Infotrieve]
8. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997; 77: 748–754.[Medline] [Order article via Infotrieve]
9. Nies AS, Andros EA, Gerber JG. Platelet alpha 2-adrenergic receptor responsiveness is increased in elderly men but not in elderly women. Clin Pharmacol Ther. 1992; 52: 605–608.[Medline] [Order article via Infotrieve]
10. Neuger J, El Khoury A, Kjellman BF, Wahlund B, Aberg-Wistedt A, Stain-Malmgren R. Platelet serotonin functions in untreated major depression. Psychiatry Res. 1999; 85: 189–198.[CrossRef][Medline] [Order article via Infotrieve]
11. Uzunova A, Ramey E, Ramwell PW. Effect of testosterone, sex and age on experimentally induced arterial thrombosis. Nature. 1976; 261: 712–713.[CrossRef][Medline] [Order article via Infotrieve]
12. Uzunova AD, Ramey ER, Ramwell PW. Arachidonate-induced thrombosis in mice: effects of gender or testosterone and estradiol administration. Prostaglandins. 1977; 13: 995–1002.[CrossRef][Medline] [Order article via Infotrieve]
13. Torres Duarte AP, Ramwell P, Myers A. Sex differences in mouse platelet aggregation. Thromb Res. 1986; 43: 33–39.[CrossRef][Medline] [Order article via Infotrieve]
14. Kohler C, Wooding W, Ellenbogen L. Intravenous arachidonate in the mouse: a model for the evaluation of antithrombotic drugs. Thromb Res. 1976; 9: 67–80.[CrossRef][Medline] [Order article via Infotrieve]
15. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol. 1977; 232: H381–H385.
16. Orchard MA, Botting JH. The influence of sex hormones on rat platelet sensitivity to adenosine-diphosphate. Thromb Haemost. 1981; 46: 496–499.[Medline] [Order article via Infotrieve]
17. Emms H, Lewis GP. Sex and hormonal influences on platelet sensitivity and coagulation in the rat. Br J Pharmacol. 1985; 86: 557–563.[Medline] [Order article via Infotrieve]
18. Miller VM, Lewis DA, Barber DA. Gender differences and endothelium- and platelet-derived factors in the coronary circulation. Clin Exp Pharmacol Physiol. 1999; 26: 132–136.[CrossRef][Medline] [Order article via Infotrieve]
19. Lewis DA, Bracamonte MP, Rud KS, Miller VM. Selected contribution: Effects of sex and ovariectomy on responses to platelets in porcine femoral veins. J Appl Physiol. 2001; 91: 2823–2830.
20. Ishihara H, Zeng D, Connolly AJ, Tam C, Coughlin SR. Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood. 1998; 91: 4152–4157.
21. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence- activated flow cytometry. J Lab Clin Med. 1994; 123: 728–740.[Medline] [Order article via Infotrieve]
22. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001; 413: 74–78.[CrossRef][Medline] [Order article via Infotrieve]
23. Leytin V, Mody M, Semple JW, Garvey B, Freedman J. Flow cytometric parameters for characterizing platelet activation by measuring P-selectin (CD62) expression: theoretical consideration and evaluation in thrombin-treated platelet populations. Biochem Biophys Res Commun. 2000; 269: 85–90.[CrossRef][Medline] [Order article via Infotrieve]
24. Moog S, Mangin P, Lenain N, Strassel C, Ravanat C, Schuhler S, Freund M, Santer M, Kahn M, Nieswandt B, Gachet C, Cazenave JP, Lanza F. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood. 2001; 98: 1038–1046.
25. Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest. 2001; 108: 477–483.[CrossRef][Medline] [Order article via Infotrieve]
26. Hechler B, Zhang Y, Eckly A, Cazenave JP, Gachet C, Ravid K. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. J Thromb Haemost. 2003; 1: 155–163.[CrossRef][Medline] [Order article via Infotrieve]
27. Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999; 104: 1731–1737.[Medline] [Order article via Infotrieve]
28. Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, Leon C, Cazenave JP, Nieswandt B, Gachet C. The P2Y(12) receptor induces platelet aggregation through weak activation of the IIbß3 integrin–a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 2001; 505: 281–290.[CrossRef][Medline]
[Order article via Infotrieve]
29. Baurand A, Eckly A, Bari N, Leon C, Hechler B, Cazenave JP, Gachet C. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost. 2000; 84: 484–491.[Medline] [Order article via Infotrieve]
30. Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Protease-activated receptors. 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood. 2002; 99: 3629–3636.
31. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407: 258–264.[CrossRef][Medline] [Order article via Infotrieve]
32. Asselin J, Gibbins JM, Achison M, Lee YH, Morton LF, Farndale RW, Barnes MJ, Watson SP. A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase C 2 in platelets independent of the integrin 2ß1. Blood. 1997; 89: 1235–1242.
33. De Marco L, Mazzucato M, Masotti A, Fenton JW, Ruggeri ZM. Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin. J Biol Chem. 1991; 266: 23776–23783.
34. Lau LF, Pumiglia K, Cote YP, Feinstein MB. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators. Biochem J. 1994; 303: 391–400.
35. Lasne D, Donato J, Falet H, Rendu F. Different abilities of thrombin receptor activating peptide and thrombin to induce platelet calcium rise and full release reaction. Thromb Haemost. 1995; 74: 1323–1328.[Medline] [Order article via Infotrieve]
36. Satoh K, Ozaki Y, Asazuma N, Yatomi Y, Ruomei Q, Kuroda K, Yang L, Kume S. Differential mobilization of tyrosine kinases in human platelets stimulated with thrombin or thrombin receptor agonist peptide. Biochem Biophys Res Commun. 1996; 225: 1084–1089.[CrossRef][Medline] [Order article via Infotrieve]
37. Oyekan AO, Botting JH. A minimally invasive technique for the study of intravascular platelet aggregation in anesthetized rats. J Pharmacol Methods. 1986; 15: 271–277.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. L. Bailey, D. C. Scantlebury, and S. S. Smyth Thrombosis and Antithrombotic Therapy in Women Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 284 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Shanmugam, J. K. Kumar, I. Selvaraj, and V. Selvaraj Hematology of Sloth Bears (Melursus ursinus ursinus) from Two Locations in India J. Wildl. Dis., April 1, 2008; 44(2): 509 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cheli, D. Jensen, P. Marchese, D. Habart, T. Wiltshire, M. Cooke, J. A. Fernandez, J. Ware, Z. M. Ruggeri, and T. J. Kunicki The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice Blood, February 1, 2008; 111(3): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-H. Leng, W. Zhang, B. Nieswandt, and P. F. Bray Effects of Estrogen Replacement Therapies on Mouse Platelet Function and Glycoprotein VI Levels Circ. Res., September 2, 2005; 97(5): 415 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Iafrati, O. Vitseva, K. Tanriverdi, P. Blair, S. Rex, S. Chakrabarti, S. Varghese, and J. E. Freedman Compensatory mechanisms influence hemostasis in setting of eNOS deficiency Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1627 - H1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Pimanda, T. Ganderton, A. Maekawa, C. L. Yap, J. Lawler, G. Kershaw, C. N. Chesterman, and P. J. Hogg Role of Thrombospondin-1 in Control of von Willebrand Factor Multimer Size in Mice J. Biol. Chem., May 14, 2004; 279(20): 21439 - 21448. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||